Drugs / Ala-Cpn10
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01838694 | Jul 2013 → Aug 2015 | systemic lupus erythematosus | Invion, Inc. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2015-08-18 | Invion, Inc. | Results Dr Glass discusses phase II lupus data with BRR inviongroup.com ↗
Australian respiratory technology company Invion Limited (ASX: IVX) is delighted to invite investors to listen to Invion’s Dr Mitchell Glass discuss the results of the Phase II clinical trial of INV103 (ala-Cpn10) in patients with systemic lupus (SLE). |
| 2015-08-16 | Invion, Inc. | Results INV103 ala-Cpn10 clinical trial in lupus complete inviongroup.com ↗
Data from patients’ cells show positive effect after one month of dosing |
| 2014-09-07 | Invion, Inc. | Results Lupus clinical trial update inviongroup.com ↗
Invion Limited (ASX: IVX) is pleased to advise that it has received interim data from its phase II clinical trial of INV103 (ala-Cpn10) in patients with Systemic Lupus Erythematosus (SLE). |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2015-08-18 | Invion, Inc. | Dr Glass discusses phase II lupus data with BRR inviongroup.com ↗ |
| 2015-08-16 | Invion, Inc. | INV103 ala-Cpn10 clinical trial in lupus complete inviongroup.com ↗ |
| 2014-09-07 | Invion, Inc. | Lupus clinical trial update inviongroup.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ala-Cpn10 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01838694 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant minimally modified Chaperonin10 (Cpn10)” NCT01838694 ↗ |
| Route | Intravenous | “administered intravenously by infusion over 60 minutes” NCT01838694 ↗ |